Actualités

Today's ADP private-sector payrolls came in below the +75K forecast and less than half the downwardly revised +95K from June.

Investors have plenty of reasons to be uncertain right now. But that has not wholly shaken companies' faith in their ability to deliver strong earnings growth this year.

Eli Lilly raised its 2026 sales forecast as its GLP-1 drugs outperformed expectations in Q2.

The S&P 500 climbed 0.6% on Wednesday, while SpaceX stock slumped more than 10% on its first quarterly report since going public

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively trad

Stock Market Today: The Dow Jones index rises Wednesday after surprise jobs data. AMD stock and SpaceX plunge on earnings.

The benchmark US stock measures were trending higher in Wednesday's premarket activity amid growing

Eli Lilly and Novo Nordisk, the world’s two largest makers of weight-loss and diabetes drugs, raised their full-year forecasts on the back of...

Eli Lilly posted a blockbuster second quarter fueled by continued demand for its portfolio of GLP-1 medications. The world’s biggest drugmaker by market value reported adjusted earnings of $8.38 a share in the period, better than the $6.01 consensus estimate among analysts polled by FactSet. Revenue surged 48% to nearly $23 billion—Wall Street was looking for $20.7 billion.

Investing.com -- Eli Lilly shares jumped more than 5% in premarket trading Wednesday after the U.S. pharma giant raised its annual revenue guidance amid strong demand for its popular weight-loss and diabetes drugs.

Mounjaro revenue jumped 91% to $9.9 billion and Zepbound brought in $4.9 billion as the drugmaker beat Wall Street estimates

Eli Lilly reported higher net income and revenue in the recent quarter, fueled by continued surging demand for its GLP-1 weight-loss drugs.

CVS beat Wall Street expectations by a wide margin in the second quarter and raised its full-year profit forecast to as much as $8.10 per share

Investing.com -- CVS Health shares jumped about 5% in premarket trading Wednesday after the company raised its full-year profit guidance following better-than-expected second-quarter results.

Aug 5 () - Eli Lilly and Co raised ‌its full-year revenue ‌forecast on Wednesday, banking ​on sustained demand for its blockbuster GLP-1 weight-loss and diabetes drugs. The ‌move comes ⁠less than a day after rival ⁠Novo Nordisk also hiked its full-year profit ​and sales ​forecast, ​banking on ‌its oral Wegovy pill to help claw back lost ground from Lilly in the lucrative ‌obesity market.

Today Federal Reserve speakers: Fed governor Lisa Cook Economic data: the Energy Information Administration’s weekly petroleum status report, U.S. services PMI, global services PMI, ADP employment survey Earnings (a.

CVS Health reports earnings Wednesday, with analysts expecting another solid quarter and looking for potential guidance upside from its Aetna insurance and Caremark pharmacy-benefit businesses.

U.S.-traded shares of Novo Nordisk are down more than 6% due to a sales shortfall for its new Wegovy weight-loss pill and a disappointing study outcome for a next-generation weight-loss drug. Overall, the company sees the potential for a full-year sales decline of up to 6%, better than its previous view that sales could drop up to 12%. Novo also disclosed that its experimental drug CagriSema failed to show comparable blood-sugar reduction to Eli Lilly’s tirzepatide in a new study of people with Type 2 diabetes.

The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.

Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early.

Pfizer (PFE) delivered earnings and revenue surprises of +13.24% and +4.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.

Eli Lilly is scheduled to report earnings Wednesday morning, with traders expecting the drugmaker’s stock could potentially approach last month’s highs following the results.

(Bloomberg) -- Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split.Most Read from BloombergBeer Dynasty Families Sell €731 Million Stake in AB InBevApple’s New CEO Taps Retired Hardware Executive for Management TeamTaco Bell Met With Michigan on Parasite Weeks Before RecallMamdani Dismisses Business Leaders Advising NYC’s Mayor’s FundS&P 5

Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...

Inspire Medical Systems (NYSE:INSP) reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The company said results exceeded its internal expectations for profitability and cash flow, prompting

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.

Earnings continue to be the market's engine, and a series of results this week from Palantir, SpaceX, and AMD are set to rev up stocks again.

The benchmark US stock measures were pointing higher before the opening bell Monday as President Don